Annovis Bio, Inc. (ANVS) - Latest Market Data

Price & Market Data

Price: $2.23

Daily Change: +$0.08 / 3.59%

Daily Range: $2.16 - $2.39

Market Cap: $94,868,368

Daily Volume: 2,606,595

Performance Metrics

1 Week: 15.27%

1 Month: 23.81%

3 Months: -0.85%

6 Months: -40.15%

1 Year: 11.43%

YTD: -32.17%

About Annovis Bio, Inc. (ANVS)

Financial insights into Annovis Bio, Inc. (ANVS). Current price: 2.23, daily change: +$0.08 / 3.59%. Market cap: 94,868,368. Performance metrics across all timeframes are updated.

Company Details

Employees: 8

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Selected stocks

ARB IOT Group Limited (ARBB)

Natuzzi, S.p.A. (NTZ)

Enlivex Ltd. (ENLV)

Verde Clean Fuels, Inc. (VGAS)